Pancreatic Cancer Drug Atebimetinib Shows 17.3-Month Survival, Favorable Tolerability at ASCO
IMRX has more than doubled off its 52-week low of $1.58 on elevated volume (2.6× avg).
Summary
Immuneering presented compelling Phase 2a clinical data for its drug atebimetinib in first-line metastatic pancreatic cancer at the ASCO Annual Meeting. The data showed a median overall survival of 17.3 months, a significant improvement over the 8.5 months for standard of care chemotherapy. Importantly, the drug also demonstrated a favorable tolerability profile with limited severe treatment-related adverse events and 84% of patients maintaining or gaining weight. This comprehensive data reinforces the drug's potential and strongly supports the ongoing global Phase 3 MAPKeeper-301 trial, which is actively recruiting.
At the time of this announcement, IMRX was trading at $5.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.3M. The 52-week trading range was $1.58 to $10.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.